Clinical trials
Hematopoietic Stem Cell Transplantation clinical trials
Below are recruiting hematopoietic stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 374 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03128034RecruitingPhase 1/Phase 2
Astatine-211 treatment before stem cell transplant for high-risk blood cancers
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
Seattle, WashingtonAges 18–75 - NCT03279094RecruitingPhase 1
Testing a half-matched bone marrow transplant for sickle cell
This early-phase study tests whether a “half-matched” donor bone marrow transplant, with special medicines to calm the immune system before transplant, can improve outcomes for people with sickle cell disease. It may help high-risk patients who have frequent complications and don’t have a fully matched donor.
Duarte, CaliforniaAges 1–30 - NCT03378102RecruitingEarly Phase 1
AdV-targeted T cells for adenovirus after bone marrow transplant
This trial tests a custom immune cell treatment (T cells made to recognize adenovirus) for people whose adenovirus infection is not improving or who cannot tolerate standard antiviral medicines after a bone marrow transplant. It aims to help your body control the virus and prevent organ complications.
Cleveland, OhioAges 3 months+ - NCT03394365RecruitingPhase 3
Tabelecleucel for EBV-related lymphoma after transplant treatment failure
This trial tests tabelecleucel, an immune therapy, for people whose EBV-associated post-transplant lymphoproliferative disease (PTLD) did not respond to rituximab and/or chemotherapy. It may help your immune system better control EBV-driven lymphoma after a transplant.
Duarte, CaliforniaAges Any age - NCT03533816RecruitingPhase 1
Gamma delta T-cell infusion after stem cell transplant
This early-phase study tests giving a special immune-cell treatment after an allogeneic (donor) stem cell transplant, plus a medication given after transplant to help the new immune system work better. It may help prevent or treat cancer returning after transplant.
Westwood, KansasAges 18–65 - NCT03665675RecruitingEarly Phase 1
Immune cell treatment to control CMV or adenovirus after transplant
This early-phase study tests donor immune cells made to recognize CMV (a virus) or adenovirus, given to help control virus reactivation after a solid organ or bone marrow transplant. It may help reduce ongoing or worsening viral infection when standard antiviral medicines are hard to tolerate or not working well.
Columbus, OhioAges 1–85 - NCT03667599Recruiting
Home care program after your stem cell transplant
This study tests whether extra home-based medical support after a stem cell transplant can help patients during recovery. If you’re eligible, a trained care team will support you at home so you’re safer and better managed after discharge.
Durham, North CarolinaAges 18–80 - NCT03670966RecruitingPhase 1/Phase 2
Targeted iodine therapy, then donor transplant for hard leukemias
This trial tests an antibody-linked radioactive iodine treatment, followed by a donor stem cell transplant, for people with relapsed or refractory high-risk acute leukemia or certain MDS. It may help patients by targeting leukemia cells and then using a new immune system to control the disease.
Seattle, WashingtonAges 18–75 - NCT03805477RecruitingPhase 2
Nintedanib for lung scarring after bone marrow transplant
This trial tests nintedanib to slow or improve bronchiolitis obliterans syndrome (BOS), a type of lung scarring, after a hematopoietic stem cell transplant. You may be considered if your breathing tests and scans show BOS, and if active infections and certain health risks are ruled out.
RiyadhAges 18 years+ - NCT03970096RecruitingPhase 2
Reduce graft-versus-host disease after stem cell transplant
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Tampa, FloridaAges 1–60 - NCT04047628RecruitingPhase 3
MS patients with active relapsing disease comparing two treatment plans
This Phase 3 study compares the best standard MS treatment (chosen by your doctors) versus an approach called autologous hematopoietic stem cell transplant (AHSCT) for people with highly active, treatment-resistant relapsing multiple sclerosis. It aims to see which option controls MS disease activity better and keeps you safer over time.
Palo Alto, CaliforniaAges 18–55 - NCT04014374Recruiting
Safety study for stem cell transplant after mogamulizumab
This study tracks safety in adults who had a stem cell transplant after taking mogamulizumab. It looks at outcomes and side effects over time, helping doctors understand risks for future patients.
Milwaukee, WisconsinAges 18 years+ - NCT04098445Recruiting
Study of lung injury in children after stem cell transplant
This study follows children and teens who get a stem cell transplant to learn how lung problems develop over time. Your participation could help doctors better predict, prevent, and manage lung injury after transplant.
San Francisco, CaliforniaAges Up to 24 years - NCT04180059RecruitingPhase 1
Anti-DP treatment after stem cell transplant to prevent relapse
This early-phase trial tests an anti-DP medicine given after an allogeneic (donor) stem cell transplant. It aims to improve outcomes by targeting immune cells linked to certain transplant match types and reducing relapse risk.
NantesAges 18–75 - NCT04195633RecruitingPhase 2
Haploidentical donor stem cell transplant to treat blood cancers
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
Seattle, WashingtonAges 6 months+ - NCT04201210RecruitingPhase 2
Stem cell transplant study for young people with severe sickle cell
This Phase 2 study tests a type of stem cell transplant that uses donor immune cells that have been specially “tweaked” to help treat sickle cell disease. It may help prevent serious sickle cell complications, but it requires careful matching and screening of organs and pregnancy status.
ViennaAges 2–35 - NCT04224558RecruitingPhase 1/Phase 2
Stem cell transplant for hard-to-control Crohn’s disease
This early-phase study tests whether a stem cell transplant can improve Crohn’s disease in teens and young adults whose disease is active and not responding to standard medicines. It may help some people who are not doing well despite several prior treatments, but it also involves intensive study procedures and safety checks.
Los Angeles, CaliforniaAges 13–28 - NCT04293562RecruitingPhase 3
Testing targeted drugs plus chemo for newly diagnosed AML
This study compares standard chemotherapy to chemotherapy plus CPX-351 and/or gilteritinib in children and young adults newly diagnosed with AML. It aims to see whether adding these targeted treatments improves outcomes, especially for certain gene changes like FLT3.
Birmingham, AlabamaAges Up to 21 years - NCT04339777RecruitingPhase 2
Bone marrow transplant for inherited immune system disorders
This trial studies how well a donor bone marrow (stem cell) transplant works for people with inherited immune system problems (called immune deficiencies). It’s for patients who haven’t improved with usual treatment or don’t have another good option.
Bethesda, MarylandAges 4–69 - NCT04375631RecruitingPhase 1
Study of chemo plus donor stem cell transplant for blood cancers
This Phase 1 trial tests a specific chemotherapy plan followed by a reduced-intensity donor stem cell transplant for people with relapsed or treatment-resistant acute myeloid leukemia (AML), certain myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It may help by using donor stem cells to rebuild the bone marrow after intensive cancer treatment, in people who are not responding well to standard therapies.
Seattle, WashingtonAges 18 years+ - NCT04380831RecruitingEarly Phase 1
Whole-body radiation plus chemo before stem cell transplant
This early-stage trial studies whether giving whole-body radiation and a chemotherapy medicine before an autologous stem cell transplant can improve severe systemic sclerosis. It aims to reset the immune system, but it requires careful safety checks and close follow-up.
Duarte, CaliforniaAges 18–65 - NCT04391335Recruiting
Breathing tests to spot lung scarring after stem cell transplant
This study checks new ways to measure breathing in children who had a stem cell transplant to better detect a lung condition called bronchiolitis obliterans syndrome. If you join, you’ll do breathing and imaging tests, and researchers will look for patterns that may help with diagnosis.
Toronto, OntarioAges 6–18 - NCT04448184RecruitingPhase 3
Platelet transfusion strategy during stem cell transplant
This trial compares how platelets are given during a stem cell transplant to help prevent bleeding. It also watches for clotting risks, since platelets can affect both bleeding and clot formation.
Calgary, AlbertaAges 18 years+ - NCT04483206RecruitingPhase 1
Personalized stem cell transplant for multiple myeloma
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
Atlanta, GeorgiaAges 18 years+
Hear when a new Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hematopoietic stem cell transplantation?
- Yes. Clin2 currently lists 374 recruiting hematopoietic stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hematopoietic stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hematopoietic stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Allogeneic Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Haploidentical Hematopoietic Stem Cell Transplantation
- Autologous Hematopoietic Stem Cell Transplantation
- Hematopoietic Stem Cell Transplant
- Stem Cell Transplantation
- Hematopoetic Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.